m+Medelevator.RU
← Поиск публикаций
Molecular biomedicine · 2026

Metabolic reprogramming in fibrosis-related diseases: underlying mechanisms and therapeutics.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Feng Yourong, Zhang Xudong, Wang Xin Joy, Chen Chen

Аннотация

Fibrosis, which is characterized by excessive extracellular matrix deposition and tissue stiffening, impairs organ function and particularly affects the heart, lungs, liver, and kidneys. The persistent activation of fibrosis-driving cells, such as myofibroblasts, lung epithelial cells, hepatic stellate cells and tubular epithelial cells, by various transcriptional cues and posttranslational modifications (PTMs) rewires cellular substrate metabolism, most notably glucose, amino acid and lipid flux, thereby recapitulating the Warburg effect originally described in cancer cells. Although the organ-specific mechanisms of fibrosis remain incompletely elucidated, different forms of fibrosis share common features of metabolic reprogramming. In this review, we first introduce the core metabolic pathways involved in fibrotic disorders including glycolysis, glutaminolysis and lipid metabolism. Next, we focus on organ-specific metabolic alterations and their regulatory mechanisms in fibrosis-related diseases, including those of the heart, lungs, liver, kidneys, skin, peritoneum and glands, and discuss their underlying mechanisms: altered enzyme expression, subcellular localization and PTMs, within each organ-specific context. In addition to their canonical catalytic functions, enzymes that participate in glucose and lipid metabolism influence fibrosis through nonenzymatic activities mediated by PTMs, including phosphorylation, acetylation, ubiquitination, and the newly recognized lactylation. We further summarize mechanistic insights across organs and metabolic crosstalk in fibrosis. Finally, we discuss the current clinical translation and applications of these pathways. This review provides a reference for further research on metabolic reprogramming, highlights the role of aberrant metabolism and its underlying mechanisms in fibrosis across organs, and identifies emerging therapeutic strategies targeting glycolysis and lipid metabolism.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты